Syncria albiglutide: Additional Phase III data

Additional data from the open-label, international Phase III Harmony 6 trial in about 500 Type II diabetics showed that once-weekly subcutaneous albiglutide plus Lantus insulin glargine led to a non-significant reduction in HbA1c from baseline to week 52 (1.01% vs. 0.85%) and a non-significant increase in the proportion of patients achieving Hb1Ac <=7% at week 52 (45% vs. 30%) vs. preprandial insulin lispro plus Lantus. Albiglutide plus Lantus did significantly reduce body weight from baseline to week 52 by 0.96 kg vs. a 1.66 kg increase with preprandial insulin lispro plus Lantus (p<0.0001). Albiglutide plus Lantus also significantly reduced FPG from baseline to week 52 vs. preprandial insulin lispro plus Lantus (27 mg vs. 16 mg, p=0.0281). Data were presented at the American Diabetes Association meeting in Philadelphia. ...